Zoetis (NYSE:ZTS) issued an update on its FY 2019 earnings guidance on Thursday morning. The company provided EPS guidance of $3.42-3.52 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.47. The company issued revenue guidance of $6.1-6.225 billion, compared to the consensus revenue estimate of $6.26 billion.Zoetis also updated its FY19 guidance to $3.42-3.52 EPS.
NYSE ZTS opened at $103.75 on Friday. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95. The firm has a market capitalization of $49.72 billion, a price-to-earnings ratio of 33.15, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. Zoetis has a one year low of $78.90 and a one year high of $103.97.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.09. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.45 billion. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. Zoetis’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.75 earnings per share. Equities analysts anticipate that Zoetis will post 3.46 earnings per share for the current year.
A number of research analysts have recently issued reports on ZTS shares. Zacks Investment Research lowered shares of Zoetis from a buy rating to a hold rating in a research note on Sunday, January 6th. UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, January 23rd. They issued a neutral rating and a $86.00 target price for the company. BMO Capital Markets raised their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a market perform rating in a report on Monday, February 25th. Stifel Nicolaus upgraded shares of Zoetis from a hold rating to a buy rating and raised their target price for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Finally, SunTrust Banks assumed coverage on shares of Zoetis in a report on Tuesday, March 19th. They issued a hold rating and a $100.00 target price for the company. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Zoetis currently has an average rating of Buy and a consensus price target of $102.85.
In other news, EVP Clinton A. Jr. Lewis sold 6,124 shares of Zoetis stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $101.60, for a total value of $622,198.40. Following the transaction, the executive vice president now owns 54,484 shares of the company’s stock, valued at $5,535,574.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $101.89, for a total transaction of $203,780.00. Following the completion of the transaction, the insider now directly owns 30,727 shares in the company, valued at approximately $3,130,774.03. The disclosure for this sale can be found here. In the last three months, insiders sold 410,333 shares of company stock worth $38,674,547. Insiders own 0.29% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Analyst Ratings Trading
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.